

Medical/Bio Research Topics II: Week 09 (29.10.2024)


# Practical Implementation of AI Models for Regression (1): Dataset Exploration and Problem Formulation

회귀 인공지능 모델 개발 실습 (1): 데이터 및 예측 문제

# Ageing

- Process of becoming older
  - Refers mainly to humans
- Biological basis [\[Jin, 2010\]](#)
  - Neither theory appears to be fully satisfactory
  - Two main theoretical categories:
    - Genetically programmed
      - Biological timetable, perhaps a continuation of childhood growth and development
    - Damage or error-related
      - Environmental assaults to living organisms

- Hallmarks of ageing [\[Guo et al., 2022\]](#)
  - Genomic instability
  - Telomere dysfunction
  - Epigenetic alterations
  - Loss of proteostasis
  - Compromise of autophagy
  - Mitochondrial dysfunction
  - Cellular senescence
  - Stem cell exhaustion
  - Altered intercellular communication
  - Deregulated nutrient sensing




[Guo et al., 2022]

Ten hallmarks of ageing subdivided into three categories

- Changes by ageing
  - Accumulation of a wide variety of molecular and cellular damage over time
    - gradual decrease in physical and mental capacity
    - growing risk of disease
    - death
  - Neither linear nor consistent
  - Only loosely associated with an individual's age in years
  - Often associated with other life transitions such as retirement, relocation to more appropriate housing, and the death of friends and partners

- Population ageing
  - Shift in distribution of a country's population towards older ages
    - Increasing median age in a population
    - By 2030, 1 in 6 people in the world will be aged 60 years or over  
[\[https://www.who.int/news-room/fact-sheets/detail/ageing-and-health\]](https://www.who.int/news-room/fact-sheets/detail/ageing-and-health)
  - Because of declining fertility rates and rising life expectancy
  - Started in high-income countries and now extended to low- and middle-income countries



[\[http://study-aids.co.uk/dissertation-blog/population-ageing/\]](http://study-aids.co.uk/dissertation-blog/population-ageing/)

**Size and proportion of the global population as related to age over time**

- Healthy ageing [<https://www.who.int/news-room/fact-sheets/detail/ageing-and-health>]
  - Proposed by the World Health Organization
  - Importance of an individual's healthspan (years lived in good health) in their lifespan (total years lived) with longevity
    - Related to non-random diversity seen in older age
  - Operationalises health as functional ability, which results from the interactions of intrinsic capacity and the environments
    - Although some of the variations in older people's health are genetic, most is due to their physical and social environments as well as their personal characteristics



# Biological Age

- Two types of age
  - Chronological age
    - Number of years an individual has been alive
    - Unchangeable
  - Biological age
    - How old an individual's cells and tissues appear to be based on their current condition
    - May be reversed

## CHRONOLOGICAL AGE

- The number of years that have passed since our birth.
- Cannot be influenced by lifestyle and eating habits.
- Has little relevance to how you feel and function.




## BIOLOGICAL AGE

- How old our cells really are, therefore, our real age
- Can be reversed by attending to your health
- The most important component to the aging process

[<https://rejuvenate.com/truage/>]

**Chronological vs. biological age**

- Departure of biological age from chronological age
  - May exhibit greatly different susceptibilities to age-related diseases and death for individuals of the same chronological age
  - Likely reflective of differences in underlying biological ageing processes
- Biological age as a biomarker of ageing
  - Individual-level measure of ageing that captures inter-individual differences in the timing of disease onset, functional decline, and death over the life course
  - Crucial to enable evaluation of interventions aimed at promoting healthier ageing, by providing a measurable outcome



[Haupt et al., 2022]

**Factors that have the potential to advance or delay ageing processes**

- How biological age is determined
  - Often by assessing an individual's genetic material
    - Telomeres (repeats of a hexameric DNA sequence capping the end of chromosomes)
      - Shorter telomeres → older biological age
    - DNA methylation (DNAm, hypo- and hyper-methylation changes at many regions across the genome)



TruAge™ vs. Everyone Else			
What we do that Zymo and Elysium don't			
While Zymo (MyDNAge) and Elysium (Index) market their biological age test to consumers all over the world, there are a few things they don't do.			
	TruAge™	MyDNAge	Index
Test over 900,000 Loci	✓	✗	✗
Custom Algorithm	✓	✗	✗
Track your lab and health information in one place	✓	✗	✗
Validated Collection Method	✓	✗	✗
Additional Testing	TruTelomere™	✗	✗
Report	50+ Pages of Interpreted Data and Clinical Recommendations	1 Page Report	3 Page Report
Time it Takes to Report Results	4-6 Weeks	6-8 Weeks	6+ Weeks

- A combination of numerous potential markers that specifically measures all important aspects of ageing processes may be the key to a valid composite biomarker of ageing [\[Hartmann et al., 2021\]](#)
  - Routine laboratory
  - Epigenetic
  - Non-epigenetic
  - Physical capability
  - Organ function
  - Cellular senescence

Potential biomarkers	Material	Age linked processes <sup>#</sup>	e-score	rc-score*	c-score
Lymphocytes/WBC [CDC] [PA]	blood/EDTA	Inflammation autoimmune disorders	-	202	2240
Insulin	blood/serum	Diabetic state	--	148	1143
Glucose/glucose fastened [PA]	blood/glucose monovette	Diabetic state	-	111	1175
C-reactive protein (CRP/hsCRP) [IA] [PA]	blood/plasma	Inflammation, cancer, cardiovascular disease	-	71	1146
Cholesterol	blood/plasma	Cardiovascular disease	-	67	896
Albumin [PA]	blood/plasma	Kidney and liver dysfunction	-	65	1062
IL6 [IA]	blood/plasma	Inflammation	-	58	979
Tumor necrosis factor alpha (TNFα) [IA]	blood/serum	Inflammation, cancer	--	51	751
Hemoglobin [CDC]	blood/EDTA	Anemia, other hematopoietic disorders	-	39	471
Insulin-like growth factor 1 (IGF-1)	blood/serum	Metabolic disease	--	29	263
LDL-cholesterol	blood/plasma	Cardiovascular disease	-	24	280
Triglycerides	blood/plasma	Cardiovascular disease	-	23	498
HDL-cholesterol	blood/plasma	Cardiovascular disease	-	23	349
Creatinine [PA]	blood/plasma	Kidney dysfunction	-	19	479
Monocytes	blood/EDTA	Inflammation	-	16	378
Glycated hemoglobin (HbA1c)	blood/EDTA	Diabetic state	-	13	220
Cystatin C	blood/plasma	Kidney dysfunction	-	12	142
N-terminal prohormone of brain natriuretic peptide (NT-proBNP)	blood/EDTA	Heart failure	-	10	119
Alkaline phosphatase [PA]	blood/plasma	Liver damage, bone disorder	-	9	252
Hematocrit/RBC [CDC]	blood/EDTA	Anemia	-	8	159
D-dimer	blood/citrate monovette	Hypercoagulable state	-	8	91
IL8 [IA]	blood/plasma	Inflammation	--	7	164
Plasminogen activator inhibitor-1 (PAI1)	blood/EDTA	Prothrombotic state in cancer and other acute phases	--	6	72
Bilirubin	blood/plasma	Liver dysfunction	-	5	46
Urea	blood/plasma	Renal dysfunction	-	3	137
IL15	blood/plasma	Inflammation	--	3	55
Mean corpuscular volume/MCV [CDC] [PA]	blood/EDTA	Anemia, other hematopoietic disorders	-	2	42
Mean corpuscular hemoglobin concentration/MCHC [CDC]	blood/EDTA	Anemia, other hematopoietic disorders	-	2	32
CD4/CD8 ratio	blood/EDTA	Immune deficiency, autoimmunity	--	1	103
C-peptide (preferable to insulin)	blood/serum	Diabetic state	-	1	32
IL1-β [IA]	blood/plasma	inflammation	--	1	5

\* rows are sorted by rc-score.

<sup>#</sup> frequently mentioned general or disease-linked processes.

[IA] = inflammaging

[PA] = Phenotypic Age

[CDC] = complete blood count

[Hartmann et al., 2021]

## Routine laboratory biomarkers of ageing



Potential biomarkers	Material	Methods	Age linked processes <sup>#</sup>	e-score	rc-score*	c-score
Telomere length (TL):			Morbidity, mortality, cell stress		191	932
Average TL	DNA	Q-PCR, TRF, TCA		--		**
TL structure	DNA	Q-FISH, Flow-FISH		---		**
Shortest TL	DNA	STELA, TeSLA		---		**
DNA damage	DNA	Various methods	Morbidity, mortality	--	174	713
Reactive oxygen species (ROS)	Tissue mitochondria	Various methods	Morbidity, cell stress, DNA/protein damage	---	168	712
Mitochondrial dysfunction	living cells, mitochondrial DNA	Various methods	Morbidity, mortality, neurodegenerative diseases	---	86	289
EVs (extracellular vesicles)	blood/plasma, liquor, cell culture supernatant	Immuno-histochemistry Western Blot, FACS	Cellular senescence, cancer	---	65	194
Autophagy	cells, cell extract	Electron microscopy immunoblotting flow cytometry	Morbidity, cancer, Parkinson's and Alzheimer's disease	---	46	207
Transforming growth factor beta (TGF- $\beta$ )	blood/serum	ELISA	Inflammation, fibrosis, cellular senescence, cancer	--	45	315
Telomerase activity	cell extract, DNA	PCR-ELISA, TRAP	Morbidity, mortality, tumor progression	---	41	169
Gut microbiome	fecal specimen	Next generation sequencing	Morbidity, mortality	--	29	101
$\alpha$ -Klotho	blood/plasma tissue	Immuno-histochemistry ELISA	Morbidity, mortality, renal function	--	20	107
Adiponectin	blood/plasma blood/EDTA	ELISA	Morbidity, mortality, frailty, metabolic syndrome, liver cirrhosis, diabetes type 2	-	14	217
Sirtuin 1 (SIRT1)	blood/serum	ELISA immuno-histochemistry PCR	Morbidity, mortality, inflammation, cancer	--	12	112
Growth differentiation factor 15 (GDF15)	blood/plasma	Proteomics immunoassays	Morbidity, organ damage (liver, heart, kidney)	--	12	63
Sirtuin 6 (SIRT6)	blood/serum	ELISA immuno-histochemistry PCR	Morbidity, mortality, diabetic risk, arthritis	--	4	50
Growth differentiation factor 11 (GDF11)	blood/plasma	Proteomics immunoassays	Morbidity	--	3	22
CXCL1	blood/plasma	Immunoassays, ELISA	Immune response, inflammation, cancer, Alzheimer's disease	--	0	15
Skin microbiome	skin swab	Next generation sequencing	Morbidity, mortality	--	0	4

\* rows are sorted by rc-score.

\*\* included in the c-score of TL.

<sup>#</sup> frequently mentioned general or disease-linked processes.

[Hartmann et al., 2021]

## Research laboratory biomarkers based on non-epigenetic measurements



Potential biomarkers	Material	Methods	Prediction	e-score	rc-score	c-score*
DNA methylation and aging clocks:					n.a.	2158
Horvath's clock	DNA (broad spectrum of tissues)	DNA methylation analysis	Chronological age	--	n.a.	214
Hannum's clock	DNA (blood)		Chronological age	--	n.a.	190
DNAm GrimAge	DNA (blood)		Biological age	--	n.a.	31
DNAm PhenoAge	DNA (blood)		Biological age	--	n.a.	26
Weidner clock	DNA (blood)		Chronological age	--	n.a.	8
EpiTOC	DNA (blood)		Biological age	---	n.a.	2
miRNA (microRNA)	RNA (blood/plasma PBMCs)	Next generation sequencing microarrays	Morbidity, mortality	---	198	635
Non-coding RNA expression profiles	RNA	RNA sequencing	Chronological age	---	167	602
exRNA (extracellular RNA)	blood/plasma	Next generation sequencing	Morbidity, mortality	---	25	119
Histone modifications:					36	73
H4K20 methylation		DNA methylation analysis mass spectrometry, HPLC, ChIP Immunohisto-chemistry	Cell stress	---	n.a.	n.a.
H4K16 acetylation				---	n.a.	n.a.
H3K4 methylation	protein extract			---	n.a.	n.a.
H3K9 methylation	from tissue DNA			---	n.a.	n.a.
H3K27 methylation				---	n.a.	n.a.
Chromatin remodeling	DNA	Chromatin remodeling assays	Chronological age	---	13	26

\* rows are sorted by c-score.

n.a.: not assigned due to high variation of terminology in literature.

[Hartmann et al., 2021]

**Research laboratory biomarkers based on epigenetic measurements**

Potential biomarkers	Method	Age linked processes <sup>#</sup>	Domain	e-score	rc-score*	c-score
<b>Physical capability</b>						
Grip strength	Physical exam	Mortality, morbidity	Strength	--	11	229
Walking speed	Physical exam	Mortality, morbidity	Locomotor function	--	3	106
Standing balance	Physical exam	Mortality, morbidity	Balance	--	1	26
Timed up and go test	Physical exam	Mortality, morbidity	Locomotor function	--	0	11
<b>Organ function</b>						
Atherosclerotic lesions	IMT, ultrasound	Mortality, CAD	Cardiovascular system	--	158	680
Muscle mass	MRI	Mortality, cardiovascular risk	Body composition	--	81	495
Systolic blood pressure	Auscultatory method	Mortality, cardiovascular risk	Cardiovascular system	--	65	844
Cognitive function	Various	Mortality, morbidity	Brain function	---	56	581
Body mass index	Calculated	Mortality CAD	Body composition	--	24	1280
Bone density	Bone density test	Mortality, morbidity	Body composition	--	17	84
Lung function	Spirometry	Mortality, morbidity	Respiratory system	--	16	84
Waist circumference	Tape measure	Mortality, cardiovascular risk	Body composition	--	3	202
<b>General well being</b>						
Health assessments	Questionnaire	Mortality, morbidity	General	--	n.a.	n.a.

\* rows are sorted by c-score.

<sup>#</sup> frequently mentioned general or disease-linked.

n.a.: not assigned due to high variation of terminology in literature.

[Hartmann et al., 2021]

## Non-blood physical capability and organ function biomarkers

Potential biomarker		Material and Methods	e-score	rc-score*	c-score
SASP	Cytokines (e.g., IL-6, IL-7, IL-15)	ELISA from Serum or EDTA plasma samples proteomics	--°	442	2646
			--°	n.a.	n.a.
			--°		
			--		
Cell cycle arrest	Chemokines (e.g., IL-8, CCL3, CCL4) Growth factors (e.g., GDF-15, activin A) p53	qPCR from blood samples/staining of cultured cells/flow cytometry NGS/microarray		n.a.	n.a.
				n.a.	n.a.
			--	66	561
			--		
SA-βGal	p16 p21	Microscopy/flow cytometry		27	422
				21	435
SAHF	Histone fragments (H3K9Me2, HP1γ)	DAPI/heterochromatin staining	---	9	359
Lamin B1		Immunohistochemistry Western Blot	---	3	19
Cell morphology (e.g., progerin)	Cell shape	Microscopy of cultured cells	---	0	12
			---	n.a.	n.a.

\* rows are sorted by rc-score.

° on average (detailed in **Supplementary Table 1, 5**).


n.a.: not assigned due to high variation of terminology in literature.

[Hartmann et al., 2021]

## Biomarkers associated with cellular senescence

# Brain Age

- Biological age estimated from information usually derived from brain MRI data
- Sums up the progression of ageing processes in the brain
  - Reflects relatively advanced or delayed brain maturation, while all individuals' brains undergo the general progression such as the thinning of grey matter




[\[https://www.brainkey.ai/blog/brain-age-how-we-calculate-it-and-what-it-means\]](https://www.brainkey.ai/blog/brain-age-how-we-calculate-it-and-what-it-means)

**Typical brain images for young (22 years) and old (83 years) individuals**



- Brain age gap (BAG, also called brain-predicted age difference, delta, etc.)
  - Difference between brain age and chronological age:  $BAG = \text{estimated brain age} - \text{chronological age}$
  - Indicates whether an individual's brain appears to have aged more or less than the population average for their actual chronological age
    - $BAG > 0$ : advanced or premature brain ageing
      - Related to functional impairment [Liem et al., 2017], brain diseases such as Alzheimer's disease [Yin et al., 2023], Parkinson's disease [Eickhoff et al., 2021], schizophrenia [Nenadic et al., 2017], stroke [Egorova et al., 2019], epilepsy [Sone et al., 2021], and diabetes mellitus [Franke et al., 2013], and mortality [Cole et al., 2017]
    - $BAG < 0$ : delayed or resilient brain ageing

**Brain aging differences between  
objective cognitive impairment (OCI) groups  
stacked-multimodal**



[Liem et al., 2017]

**Premature brain ageing ( $BAG > 0$ ) in cognitive impairment**




MCI, mild cognitive impairment  
AD, Alzheimer's disease  
FTD, frontotemporal dementia  
DLB, dementia with Lewy bodies

[Lee et al., 2022]


**Advanced brain ageing (BAG > 0) in brain diseases**






[Cole et al., 2017]

**Comparison of survival rate: low BAG vs. high BAG**



[Cole et al., 2017]

**Receiver operator characteristic (ROC) curves for four survival models**



[Park et al., In Review]

**Resilient brain ageing (BAG < 0) in superageing**

# Regression in Machine Learning

- Models the relationship between input features (predictors) and the target variable (dependenct variable)
- Purpose
  - Understanding the relationship between input features and continuous target variables
  - Predicting continuous target values for new sets of input features

- Supervised learning technique for predicting continuous output values
  - Traditional methods
    - Linear regression: simple, multiple
    - Non-linear regression: polynomial, support vector regression
  - Ensemble methods
    - Bagging-based methods: random forests, extra trees
    - Boosting-based methods: AdaBoost (Adaptive Boosting), Gradient Boosting Machines (GBM), XGBoost (eXtreme Gradient Boosting), LightGBM, CatBoost (Categorical Boosting)
    - Stacking: combining predictions from multiple models

## – Deep learning-based regression

- Feedforward Neural Network (FNN) / Multilayer Perceptron (MLP)
- Specialized architectures
  - Convolutional Neural Network (CNN) for spatial data regression
  - Recurrent Neural Network (RNN) and Long Short-Term Memory (LSTM) for sequential data regression
  - Transformer-based models for complex sequential data regression

## – Hybrid approaches

- Combining traditional methods with ensemble techniques or neural networks
- Automated machine learning (AutoML) systems incorporating various regression techniques

- Types of regression problems
  - Based on the nature of the relationship:
    - Linear regression: modeling linear relationships
    - Nonlinear regression: modeling complex, nonlinear relationships
  - Based on the number of output variables
    - Univariate regression: predicting a single output variable
    - Multivariate regression: predicting multiple output variables simultaneously

- Regression performance
  - Mean Absolute Error (MAE)
    - Average of absolute differences between predicted and actual values
    - Range: 0 to  $\infty$  (lower is better)
    - In the same unit as the target variable
    - Less sensitive to outliers
  - Mean Squared Error (MSE)
    - Average of squared differences between predicted and actual values
    - Range: 0 to  $\infty$  (lower is better)
    - Penalizes larger errors more heavily
    - Harder to interpret as being in squared units
    - Sensitive to outliers



## – Root Mean Squared Error (RMSE)

- Square root of MSE
- Range: 0 to  $\infty$  (lower is better)
- In the same unit as the target variable
- Still sensitive to outliers, but less than MSE

## – R-squared (coefficient of determination)


- Proportion of variance in the target variable predictable from input features
  - $R^2 = 1 - (\text{residual sum of squares} / \text{total sum of squares})$
- Range:  $-\infty$  (can be negative for poorly fitting models, especially when the model is not fitted with an intercept term) via 0 (just predicting the mean) to 1 (perfect fit)
- Represents the fraction of variance explained by the model
  - $R^2 = 1 - \text{Fraction of Variance Unexplained (FVU)}$

## – Correlation coefficient

- Measure of linear correlation between predicted and actual values
- Range: -1 (perfect negative correlation) via 0 (no linear correlation) to 1 (perfect positive correlation)
- Measures strength and direction of linear relationship

# Brain Age Estimation

- Process of predicting an individual's biological brain age based on brain features usually extracted from MRI data
- Aimed to assess brain health status
  - Life-long, multidimensional, dynamic state consisting of cognitive, emotional, and motor domains underpinned by physiological processes [\[Chen et al., 2022\]](#)



[Franke et al., 2010]

**Estimation of brain age**

- Methodology
  - Models chronological age using various brain features
  - Develops brain age estimation models using supervised learning algorithms
- Input data
  - Single or multi-modal brain MRI data, including structural MRI (sMRI), functional MRI (fMRI), and diffusion-weighted MRI (dMRI)
  - Quantitative features such as brain volume, cortical thickness, or white matter integrity

- Applications
  - Assessment of various brain functions, including cognitive and motor functions
  - Early diagnosis of neurodegenerative diseases (e.g., Alzheimer's disease)
  - Development of personalized intervention strategies for brain health improvement

# Human Connectome Project (HCP)

- Launched in 2009 as a Blueprint Grand Challenge by the National Institutes of Health in the US
- Maps the neural pathways that underlie human brain function
  - To identify functionally distinct subdivisions of the human brain
  - To understand the relationships among the subdivisions
- Acquires and shares data about the structural and functional connectivity of the human brain


- HCP original study
  - HCP Young Adult (HCP-YA)
    - Age: 22-35 years
  - 1200 subjects data release (S1200)
    - Released on 1 March 2017
    - 1,206 healthy young adult participants collected in 2012-2015
    - Imaging and behavioural data
      - 3T MRI data for 1,113 participants
      - 3T HCP protocol (MRI and behaviour) retest data for 46 participants
      - Multimodal 7T MRI data for 184 participants
  - S1200 extensively processed functional MRI data
    - Released on 21 July 2017



- HCP lifespan studies
  - Lifespan developing human connectome project
    - Age: 20-44 weeks post-conception
  - Lifespan baby connectome project
    - Age: 0-5 years
  - HCP Development (HCP-D)
    - Age: 5-21 years
  - HCP Aging (HCP-A)
    - Age: 36-100 years


## – Lifespan 2.0 release

- Released on 26 February 2021
- HCP-A & HCP-D
  - HCP-A: 725 healthy participants
  - HCP-D: 652 healthy participants
  - 22+ TB of data per project
- Imaging and behavioural data at cross-sectional visit 1 (V1)
  - Unprocessed V1 imaging data for all included modalities
  - Preprocessed structural and functional imaging data
  - Non-imaging demographic and behavioral assessment data



HUMAN  
Connectome  
PROJECT

# Human Connectome Project Milestones



[Elam et al., 2021]

Milestones over the HCP timeline


# Dataset

- HCP-A dataset ( $n = 722$ )
  - Training set:  $n = 660$ 
    - Maps from sMRI data: `train/{Brain,GM,WM,CSF}/001-660.nii.gz`
    - Maps from dMRI data: `train/{FA,MD,AD,RD}/001-660.nii.gz`
    - Sex (0 = female, 1 = male): `train/Subjects.csv: Sex`
    - Age (in years): `train/Subjects.csv: Age`


– Test set:  $n = 62$

- Maps from sMRI data: `test/{Brain,GM,WM,CSF}/001-062.nii.gz`
- Maps from dMRI data: `test/{FA,MD,AD,RD}/001-062.nii.gz`
- Sex (0 = female, 1 = male): `test/Subjects.csv: Sex`
- Age (in years): hidden


Training set



Test set






Distribution of age and sex for training and test sets



- Preprocessing of sMRI data
  - Correction for intensity non-uniformity (bias field)
  - Segmentation into grey matter, white matter, and cerebrospinal fluid
  - Normalisation to the Montreal Neurological Institute (MNI) template brain space





**Dimensions:**  $208 \times 300 \times 320$

**Voxel depth:** 32-bit real

**Voxel size:**  $0.8 \text{ mm} \times 0.8 \text{ mm} \times 0.8 \text{ mm}$







Image intensity distribution



Mixture of Gaussians model




**Segmentation into different tissues**




- Maps from sMRI data
  - Brain map in the MNI template brain space
  - Grey matter (GM) probability (partial volume fraction) map in the MNI template brain space
  - White matter (WM) probability (partial volume fraction) map in the MNI template brain space
  - Cerebrospinal fluid (CSF) probability (partial volume fraction) map in the MNI template brain space


Brain



GM



WM



CSF



**1 mm:**

**Dimensions:**  $157 \times 189 \times 156$


**Voxel size:**  $1.0 \text{ mm} \times 1.0 \text{ mm} \times 1.0 \text{ mm}$

**2 mm:**


**Dimensions:**  $79 \times 95 \times 79$

**Voxel size:**  $2.0 \text{ mm} \times 2.0 \text{ mm} \times 2.0 \text{ mm}$

**Maps from sMRI data**



- Processing of dMRI data
  - Correction for head motion, eddy current-induced distortion, and susceptibility artifact (B0 inhomogeneity-induced distortion)
  - Diffusion tensor modelling
  - Computation of diffusion tensor metrics
  - Normalisation to the MNI template brain space







**99 volumes:**


**Dimensions:**  $140 \times 140 \times 92$

**Voxel depth:** 32-bit real

**Voxel size:**  $1.5 \text{ mm} \times 1.5 \text{ mm} \times 1.5 \text{ mm}$











[<https://www.blog.brainsightai.com/post/from-dti-to-hardi>]

## Diffusion tensor modelling











$$FA = \sqrt{\frac{1}{2}} \cdot \frac{\sqrt{(\lambda_1 - \lambda_2)^2 + (\lambda_2 - \lambda_3)^2 + (\lambda_3 - \lambda_1)^2}}{\sqrt{(\lambda_1)^2 + (\lambda_2)^2 + (\lambda_3)^2}}$$




[DeSouza et al., 2016]

## Computation of diffusion tensor metrics




- Maps from dMRI data
  - Fractional anisotropy (FA) map in the MNI template brain space
  - Mean diffusivity (MD) map in the MNI template brain space
  - Axial diffusivity (AD) map in the MNI template brain space
  - Radial diffusivity (RD) map in the MNI template brain space


FA




MD



AD



RD



**1 mm:**

**Dimensions:**  $157 \times 189 \times 156$

**Voxel size:**  $1.0 \text{ mm} \times 1.0 \text{ mm} \times 1.0 \text{ mm}$

**2 mm:**

**Dimensions:**  $79 \times 95 \times 79$

**Voxel size:**  $2.0 \text{ mm} \times 2.0 \text{ mm} \times 2.0 \text{ mm}$

**Maps from dMRI data**

- Target variable
  - Age (in years)
- Brain age estimation performance
  - MAE for the test set ( $n = 62$ )
    - Average of absolute differences between predicted and actual ages across the test set
    - Ranges from 0 to  $\infty$  (lower is better)